61:@0.890196:0.957873:0.906071:0.957873:0.906071:0.938882:0.890196:0.938882:0.007284:0.008591
3:@0.941813:0.310836:0.963291:0.310836:0.963291:0.263358:0.941813:0.263358:0.021478
PATIENT-DERIVED OVARIAN CANCER ORGANOIDS MIMIC CLINICAL RESPONSE AND:@0.411230:0.057372:0.882353:0.057372:0.882353:0.040253:0.411230:0.040253:0.007583:0.007097:0.006387:0.003511:0.006985:0.008759:0.005640:0.005155:0.008423:0.006985:0.008423:0.003511:0.007620:0.006985:0.008423:0.002988:0.008328:0.006966:0.007919:0.008423:0.003511:0.007919:0.008759:0.002988:0.008178:0.007919:0.008759:0.008255:0.006985:0.008423:0.002988:0.008442:0.008311:0.008292:0.007919:0.008759:0.008442:0.003511:0.008423:0.007807:0.002988:0.011112:0.003511:0.011112:0.003511:0.008255:0.002988:0.008255:0.006481:0.003511:0.008759:0.003511:0.008177:0.007919:0.006294:0.002988:0.008423:0.006871:0.007807:0.008050:0.008442:0.008759:0.007807:0.006985:0.002801:0.007919:0.008759:0.008423
EXHIBIT HETEROGENEOUS INTER- AND INTRAPATIENT DRUG RESPONSES:@0.468171:0.073247:0.882352:0.073247:0.882352:0.056128:0.468171:0.056128:0.006985:0.007527:0.008685:0.003511:0.008236:0.003511:0.006201:0.002988:0.008685:0.006985:0.006387:0.006985:0.008309:0.008442:0.008404:0.006985:0.008759:0.006985:0.008442:0.008367:0.007807:0.002988:0.003511:0.008759:0.006387:0.006985:0.008423:0.005155:0.002800:0.007919:0.008759:0.008423:0.002988:0.003511:0.008759:0.006387:0.008423:0.007919:0.007581:0.007097:0.006387:0.003511:0.006985:0.008759:0.006201:0.002988:0.008423:0.008367:0.008367:0.008404:0.002988:0.008423:0.006873:0.007807:0.008050:0.008442:0.008759:0.007807:0.006871:0.007807
Abstract:@0.147059:0.126494:0.242873:0.126494:0.242873:0.098384:0.147059:0.098384:0.012318:0.012812:0.012028:0.010343:0.013103:0.012144:0.012725:0.010343
There remains an unmet need for preclinical models to enable personalized therapy :@0.147059:0.168344:0.886464:0.168344:0.886464:0.147971:0.147059:0.147971:0.011470:0.011311:0.009039:0.007442:0.009039:0.007350:0.007442:0.009039:0.017577:0.009085:0.005615:0.011619:0.007670:0.007350:0.009085:0.011756:0.007350:0.011413:0.011756:0.017485:0.009131:0.006437:0.007350:0.011598:0.009106:0.009108:0.011391:0.007350:0.006026:0.010843:0.007807:0.007350:0.011071:0.007442:0.009108:0.008765:0.005250:0.005615:0.011756:0.005547:0.009108:0.009405:0.005250:0.007350:0.017485:0.011276:0.011322:0.008948:0.005250:0.007670:0.007350:0.006209:0.011048:0.007350:0.009039:0.011687:0.009108:0.010911:0.005182:0.009039:0.007350:0.011505:0.009039:0.007624:0.007875:0.010843:0.011687:0.009405:0.005250:0.005615:0.008834:0.009108:0.011391:0.007350:0.006620:0.011299:0.009039:0.007898:0.008811:0.011094:0.009724:0.004109
for ovarian cancer (OC) patients. Here, we evaluate the capacity of patient-derived :@0.147059:0.188923:0.886443:0.188923:0.886443:0.168550:0.147059:0.168550:0.006026:0.010843:0.007807:0.008377:0.010866:0.009838:0.009085:0.007807:0.005798:0.009085:0.011756:0.008377:0.009108:0.009085:0.011596:0.008994:0.009039:0.007807:0.008377:0.006939:0.016778:0.014678:0.006939:0.008377:0.011368:0.008811:0.006437:0.005547:0.009039:0.011391:0.006437:0.007670:0.004497:0.008377:0.016207:0.009039:0.007442:0.008743:0.004497:0.008377:0.014518:0.009039:0.008377:0.009336:0.009838:0.009405:0.004908:0.011596:0.008811:0.006209:0.009039:0.008377:0.006620:0.011299:0.009039:0.008377:0.009108:0.008811:0.011368:0.009291:0.008994:0.005273:0.006437:0.009724:0.008377:0.010843:0.006209:0.008377:0.011368:0.008811:0.006437:0.005547:0.009039:0.011391:0.006437:0.007533:0.011324:0.009039:0.007807:0.005547:0.009635:0.009106:0.011391:0.004109
organoids (PDOs) to predict clinical drug response and functional consequences of :@0.147059:0.209502:0.886368:0.209502:0.886368:0.189129:0.147059:0.189129:0.010843:0.007624:0.009861:0.009085:0.011596:0.010843:0.005547:0.011391:0.007670:0.007761:0.006939:0.011664:0.016504:0.016253:0.007670:0.006939:0.007761:0.006209:0.011048:0.007761:0.011071:0.007442:0.009108:0.011391:0.005547:0.009106:0.006437:0.007761:0.008765:0.005250:0.005615:0.011756:0.005545:0.009108:0.009405:0.005250:0.007761:0.011391:0.007967:0.011413:0.009861:0.007761:0.007442:0.009039:0.007510:0.011505:0.010843:0.011619:0.007875:0.009039:0.007761:0.009085:0.011596:0.011391:0.007761:0.006369:0.011413:0.011596:0.009108:0.006437:0.005547:0.010843:0.011687:0.009405:0.005250:0.007761:0.008994:0.010843:0.011619:0.007875:0.009106:0.010706:0.011347:0.009039:0.011596:0.008994:0.009039:0.007670:0.007761:0.010843:0.006209:0.004109
tumor heterogeneity. We included 36 whole-genome characterized PDOs from 23 OC :@0.147059:0.230080:0.886464:0.230080:0.886464:0.209707:0.147059:0.209707:0.006163:0.011413:0.017485:0.010843:0.007807:0.005456:0.011299:0.009131:0.006209:0.009039:0.007442:0.011048:0.009656:0.009039:0.011596:0.009039:0.005273:0.006437:0.007989:0.004497:0.005456:0.018649:0.009039:0.005456:0.005615:0.011596:0.008765:0.004908:0.011345:0.011322:0.009108:0.011391:0.005456:0.010432:0.010432:0.005456:0.014789:0.011302:0.010932:0.005184:0.009039:0.007533:0.009656:0.009039:0.011596:0.010843:0.017485:0.009039:0.005456:0.008765:0.011391:0.009085:0.007898:0.009291:0.009108:0.006209:0.009039:0.007807:0.005615:0.008834:0.009108:0.011391:0.005456:0.011664:0.016504:0.016253:0.007670:0.005456:0.006414:0.007442:0.010843:0.017645:0.005456:0.010432:0.010432:0.005456:0.016778:0.014678:0.004109
patients with known clinical histories. OC PDOs maintain genomic features of the :@0.147059:0.250659:0.886526:0.250659:0.886526:0.230286:0.147059:0.230286:0.011368:0.008811:0.006437:0.005547:0.009039:0.011391:0.006437:0.007670:0.008240:0.014723:0.005273:0.006620:0.011459:0.008240:0.010706:0.011596:0.010866:0.014723:0.011756:0.008240:0.008765:0.005250:0.005615:0.011756:0.005545:0.009108:0.009405:0.005250:0.008240:0.011459:0.005615:0.007510:0.006209:0.010843:0.007807:0.005547:0.009039:0.007670:0.004497:0.008240:0.016775:0.014678:0.008240:0.011664:0.016501:0.016253:0.007670:0.008240:0.017577:0.009085:0.005615:0.011391:0.006551:0.009085:0.005615:0.011756:0.008240:0.009656:0.009039:0.011596:0.010843:0.017645:0.005547:0.008994:0.008240:0.006026:0.009291:0.008811:0.006163:0.011413:0.007442:0.009039:0.007670:0.008240:0.010843:0.006209:0.008240:0.006620:0.011299:0.009039:0.004109
original tumor lesion and recapitulate patient response to neoadjuvant carboplatin/:@0.147059:0.271238:0.882385:0.271238:0.882385:0.250865:0.147059:0.250865:0.010843:0.007807:0.005615:0.009861:0.005615:0.011687:0.009405:0.005250:0.008309:0.006163:0.011413:0.017488:0.010843:0.007807:0.008309:0.005182:0.009039:0.007601:0.005547:0.010845:0.011756:0.008309:0.009085:0.011598:0.011391:0.008309:0.007444:0.009106:0.009108:0.008811:0.011071:0.005273:0.006163:0.011550:0.005433:0.008811:0.006209:0.009039:0.008309:0.011368:0.008811:0.006437:0.005547:0.009039:0.011391:0.006437:0.008309:0.007442:0.009039:0.007510:0.011502:0.010845:0.011619:0.007875:0.009039:0.008309:0.006209:0.011048:0.008309:0.011596:0.009108:0.011139:0.009291:0.011048:0.004953:0.011345:0.009838:0.009085:0.011391:0.006437:0.008309:0.009108:0.009085:0.007715:0.011254:0.010820:0.011162:0.005433:0.008811:0.006437:0.005615:0.011756:0.007099
paclitaxel combination treatment. PDOs display inter- and intrapatient drug response :@0.147059:0.291816:0.886507:0.291816:0.886507:0.271444:0.147059:0.271444:0.011368:0.009291:0.008765:0.005250:0.005273:0.006551:0.009291:0.009882:0.008948:0.005250:0.005981:0.008994:0.010843:0.017394:0.010820:0.005615:0.011687:0.008811:0.006437:0.005547:0.010843:0.011756:0.005981:0.006437:0.007442:0.009291:0.008811:0.006437:0.017485:0.009039:0.011391:0.006437:0.004497:0.005981:0.011664:0.016504:0.016253:0.007670:0.005981:0.011391:0.005615:0.007510:0.011160:0.005433:0.008925:0.009724:0.005981:0.005615:0.011391:0.006209:0.009039:0.007236:0.007533:0.005981:0.009085:0.011596:0.011391:0.005981:0.005615:0.011391:0.006437:0.007898:0.008811:0.011365:0.008813:0.006437:0.005549:0.009039:0.011391:0.006437:0.005981:0.011391:0.007967:0.011413:0.009861:0.005981:0.007442:0.009039:0.007510:0.011505:0.010843:0.011619:0.007875:0.009039:0.004109
heterogeneity to chemotherapy and targeted drugs, which can partially be explained by :@0.147059:0.312395:0.886487:0.312395:0.886487:0.292022:0.147059:0.292022:0.011299:0.009131:0.006209:0.009039:0.007442:0.011048:0.009656:0.009039:0.011596:0.009039:0.005273:0.006437:0.009724:0.004725:0.006209:0.011048:0.004725:0.008765:0.011302:0.009039:0.017483:0.010822:0.006617:0.011302:0.009039:0.007896:0.008811:0.011094:0.009724:0.004725:0.009085:0.011596:0.011391:0.004725:0.006551:0.009085:0.007624:0.009656:0.009131:0.006209:0.009108:0.011391:0.004725:0.011391:0.007967:0.011413:0.009724:0.007670:0.004497:0.004725:0.014792:0.011459:0.005547:0.008765:0.011459:0.004725:0.009108:0.009085:0.011756:0.004725:0.011368:0.009085:0.007967:0.006437:0.005798:0.009405:0.005387:0.005182:0.009724:0.004725:0.011254:0.009039:0.004725:0.009108:0.010089:0.011162:0.005433:0.009085:0.005615:0.011596:0.009108:0.011391:0.004725:0.010843:0.009724:0.004109
genetic aberrations. PDO drug screening identifies high responsiveness to at least one :@0.147059:0.332974:0.886370:0.332974:0.886370:0.312601:0.147059:0.312601:0.009656:0.009039:0.011596:0.009131:0.006437:0.005547:0.008994:0.005889:0.009108:0.011251:0.009039:0.007807:0.007898:0.008811:0.006437:0.005547:0.010843:0.011619:0.007670:0.004497:0.005889:0.011664:0.016504:0.016412:0.005889:0.011391:0.007967:0.011413:0.009861:0.005889:0.007875:0.008994:0.007442:0.009106:0.009039:0.011756:0.005615:0.011459:0.009861:0.005889:0.005547:0.011322:0.009039:0.011391:0.006437:0.005615:0.005684:0.005615:0.009039:0.007670:0.005889:0.011459:0.005615:0.009930:0.011459:0.005889:0.007442:0.009039:0.007510:0.011505:0.010843:0.011619:0.007601:0.005547:0.009633:0.009039:0.011596:0.009039:0.007533:0.007670:0.005889:0.006209:0.011048:0.005889:0.008811:0.006437:0.005889:0.005182:0.009291:0.009291:0.007510:0.006437:0.005889:0.010843:0.011598:0.009039:0.004109
drug for 88% of patients. PDOs are valuable preclinical models that can provide insights :@0.147059:0.353553:0.886462:0.353553:0.886462:0.333180:0.147059:0.333180:0.011391:0.007967:0.011413:0.009861:0.004154:0.006026:0.010843:0.007807:0.004154:0.010432:0.010432:0.015043:0.004154:0.010843:0.006209:0.004154:0.011365:0.008811:0.006437:0.005547:0.009039:0.011391:0.006437:0.007670:0.004497:0.004154:0.011667:0.016501:0.016253:0.007670:0.004154:0.009085:0.007444:0.009039:0.004154:0.009838:0.009402:0.004908:0.011596:0.009108:0.010911:0.005182:0.009039:0.004154:0.011071:0.007444:0.009106:0.008765:0.005250:0.005615:0.011756:0.005547:0.009108:0.009405:0.005250:0.004154:0.017485:0.011276:0.011322:0.008948:0.005250:0.007670:0.004154:0.006620:0.011391:0.008811:0.006437:0.004154:0.009108:0.009085:0.011756:0.004154:0.011071:0.007442:0.010866:0.009838:0.005547:0.011322:0.009039:0.004154:0.005615:0.011619:0.007601:0.005615:0.009930:0.011094:0.006437:0.007670:0.004109
in drug response for individual patients with OC, complementary to genetic testing. :@0.147059:0.374131:0.886395:0.374131:0.886395:0.353758:0.147059:0.353758:0.005615:0.011756:0.007076:0.011391:0.007964:0.011413:0.009861:0.007076:0.007442:0.009039:0.007510:0.011505:0.010843:0.011619:0.007875:0.009039:0.007076:0.006026:0.010843:0.007807:0.007076:0.005615:0.011596:0.011391:0.005547:0.009838:0.005547:0.011048:0.011596:0.009405:0.005250:0.007076:0.011368:0.008811:0.006437:0.005547:0.009039:0.011391:0.006437:0.007670:0.007076:0.014723:0.005273:0.006620:0.011459:0.007076:0.016778:0.014678:0.004497:0.007076:0.008994:0.010843:0.017280:0.011162:0.005182:0.009039:0.017485:0.009039:0.011391:0.006551:0.009085:0.008400:0.009724:0.007076:0.006209:0.011048:0.007076:0.009656:0.009039:0.011596:0.009131:0.006437:0.005547:0.008994:0.007076:0.006209:0.009039:0.007512:0.006437:0.005615:0.011459:0.009679:0.004497:0.004109
Generating PDOs of multiple tumor locations can improve clinical decision making and :@0.147059:0.394710:0.886416:0.394710:0.886416:0.374337:0.147059:0.374337:0.015819:0.009039:0.011596:0.009039:0.007898:0.008811:0.006437:0.005615:0.011459:0.009861:0.003675:0.011664:0.016501:0.016255:0.007670:0.003675:0.010843:0.006209:0.003675:0.017280:0.011550:0.004908:0.006437:0.005273:0.011162:0.005182:0.009039:0.003675:0.006163:0.011413:0.017485:0.010843:0.007807:0.003675:0.005182:0.011274:0.009108:0.008811:0.006437:0.005547:0.010843:0.011619:0.007670:0.003675:0.009108:0.009085:0.011756:0.003675:0.005615:0.017280:0.011071:0.007442:0.010866:0.009633:0.009039:0.003675:0.008765:0.005250:0.005615:0.011756:0.005547:0.009106:0.009405:0.005250:0.003675:0.011322:0.009108:0.008994:0.005615:0.007601:0.005547:0.010843:0.011756:0.003675:0.017577:0.009405:0.010706:0.005615:0.011459:0.009861:0.003675:0.009085:0.011598:0.011391:0.004109
increase our knowledge on genetic and drug response heterogeneity.:@0.147059:0.415289:0.719710:0.415289:0.719710:0.394916:0.147059:0.394916:0.005615:0.011596:0.008994:0.007442:0.009291:0.009291:0.007875:0.009039:0.004109:0.010818:0.011413:0.007807:0.004109:0.010706:0.011596:0.010866:0.014792:0.005182:0.009108:0.011391:0.009656:0.009039:0.004109:0.010843:0.011756:0.004109:0.009656:0.009039:0.011596:0.009131:0.006437:0.005547:0.008994:0.004109:0.009085:0.011596:0.011391:0.004109:0.011391:0.007967:0.011413:0.009861:0.004109:0.007442:0.009039:0.007510:0.011502:0.010845:0.011619:0.007873:0.009039:0.004109:0.011299:0.009131:0.006209:0.009039:0.007442:0.011048:0.009656:0.009039:0.011596:0.009039:0.005273:0.006437:0.007989:0.004497
 :@0.147059:0.433075:0.151167:0.433075:0.151167:0.412702:0.147059:0.412702:0.004109
 :@0.147059:0.450860:0.151167:0.450860:0.151167:0.430487:0.147059:0.430487:0.004109
 :@0.147059:0.469929:0.153405:0.469929:0.153405:0.452117:0.147059:0.452117:0.006346
 :@0.147059:0.505354:0.153405:0.505354:0.153405:0.487542:0.147059:0.487542:0.006346
 :@0.147059:0.523746:0.153405:0.523746:0.153405:0.505934:0.147059:0.505934:0.006346
 :@0.147059:0.559171:0.153405:0.559171:0.153405:0.541359:0.147059:0.541359:0.006346
 :@0.147059:0.612381:0.153405:0.612381:0.153405:0.594570:0.147059:0.594570:0.006346